Oxford Biomedica slumps as clinical trial is put on hold
3rd Jun 2013 08:25
Shares of gene-based biopharmaceutical company Oxford Biomedica fell sharply after it confirmed clinical trials of its eye products have been put on hold. "RetinoStat Phase I, StarGen Phase I/IIa and UshStat Phase I/IIa studies, (have been paused) as a precautionary measure, whilst the company inve
Read moreMonday broker round-up UPDATE
3rd Jun 2013 07:22
Anglo Pacific Group: Finncap cuts target price from 320p to 279p staying with its buy recommendation. Ashtead Group: Citi takes target price from 660p to 750p and maintains a buy recommendation. Centrica: Berenberg ups target price from 370p to 380p keeping a hold recommendation. Coal of Afica: I
Read moreOxford Biomedica bags Novartis leukaemia deal
1st May 2013 09:15
Pharmaceutical giant Novartis has signed up biotech firm Oxford Biomedica to provide its gene delivery technology for a programme targeting various forms of leukaemia. The deal, which is worth between £2.5m and £4.0m to Oxford Biomedica over the next 12 months, will see the Oxford company's LentiVe
Read moreRevenue rises to 7.8m pounds in full year at Oxford Biomedica
27th Feb 2013 10:30
Gene-based biopharmaceutical company Oxford BioMedica has reported that revenue rose to 7.8m pounds in the full year 2012 from 7.7m pounds one year earlier. In its preliminary results for the year ending December 31st, the company stated that fundraising of £11.6m was completed in July 2012 with ne
Read moreOxford BioMedica halts trial due to poor recruitment
10th Oct 2012 10:25
Oxford BioMedica, a gene-based biopharmaceutical company, has made a strategic decision to close the US trial of its TroVax product on patients with progressive hormone refractory prostate cancer (HRPC) because recruitment has been much slower than originally anticipated. This is largely because co
Read moreSmall caps round-up: Brady, Oxford BioMedica, Densitron Tech
31st Aug 2012 12:48
Brady, a provider of trading, risk management and settlement solutions to the energy, metals and commodities sectors, has said that it is in a payment dispute over software with a customer that it signed in 2011. The firm said the customer has made payments to Brady totalling £288,000, but has "no
Read moreSmall Caps round-up: eXpansys, Oxford Biomedica, Dawson International
8th Aug 2012 10:15
eXpansys, the online electronics retailer has delivered a 33 per cent increase in turnover in the 12 months to the end of April. Total revenues for the year were 108.5m pounds, up 24pc on a like-for-like basis. Profits before tax were 4.3m pounds, a rise of 27pc on the prior year. The market had cle
Read moreSmall caps round-up: Quadrise, Software Radio, Motive Television ...
8th Jun 2012 11:36
Quadrise Fuels International, an emulsion fuels supplier, has admitted that during its first sea-borne assessment on a Mærsk container ship it was not possible to fully optimise engine performance, as the test configuration afforded limited scope for relevant 'in service' adjustments, but that the r
Read moreSmall caps round-up: Sportech, Silverdell, Oxford BioMedica
11th May 2012 12:35
Brooks Pierce, the Executive Director of Sportech, has resigned with immediate effect to 'pursue other business interests'. No replacement has yet been appointed, but the company was keen to announce that it had appointed an executive search business to 'seek suitable candidates to further augment S
Read moreSmall caps round-up: Omega Diagnostics, Oxford Biomedica, i-design ...
16th Apr 2012 10:58
The cash-point marketing company i-design said that revenues for the first half of its current financial year will be ahead of the same period of 2011. The group creates advertising solutions for banks and third parties through cash-point screens. A new contract with a Canadian bank has boosted turn
Read moreSmall caps round-up: Gable, Motive Television, Oxford BioMedica...
12th Mar 2012 07:47
Gable Holdings, a non-life insurance company, has reported that its performance in the second half, considering the traditional cyclicality of certain of our products, was in line with expectations. In the UK, the ATE product showed strong growth and which has continued into 2012, while construction
Read moreAnother director dealing for Dunelm; AZ Electronic tech officer makes sale
8th Mar 2012 15:35
Donna Wharton, wife of Nick Wharton, the Chief Executive of homewares firm Dunelm, has topped up her stake in the company with 9,500 shares. Wharton's purchase, which saw her buy the shares at 480.00p each for a total of £45,600, came just a day after Will Adderley, Executive Deputy Chairman, anno
Read moreSmall caps round-up: Arena, RedHot Media, Vp...
10th Feb 2012 11:09
Gene-based biopharmaceutical company Oxford Biomedia has announced that its Chief Financial Officer (CFO), Andrew Wood, has stepped down and will be replaced by Tim Watts with immediate effect. Watts has over 30 years' experience in leading multinational businesses and was most recently CFO at Archi
Read moreLondon close: Financials lead the way higher
15th Dec 2011 16:56
Footsie limped back above the 5,400 level in thin trade, with financial stocks leading the way. OLD MUTUAL SURGES AFTER DISPOSAL South African savings and insurance group Old Mutual was the best performing blue-chip after announcing that it is to sell its Nordic business Skandia AB for £2.1bn in
Read moreLondon midday: Old Mutual and miners provide a lift
15th Dec 2011 11:46
The Footsie held on to gains by lunchtime, breaking through the 5,400 level, with strong gains for Old Mutual and the miners lifted London's blue chip index 0.6% higher. In domestic news, the volume of UK retail sales fell by 0.4% in November compared to the month before, according to the latest da
Read more